NCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
Clinical Trials
14 trialsNCT03994627 2024-12-16
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Eli Lilly and Company
Approved for marketing
NCT03086369 2022-06-28
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT02377752 2021-02-17
A Study of Olaratumab in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02677116 2020-05-20
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02326025 2019-11-21
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT00913835 2019-09-26
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02783599 2019-08-12
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT00918203 2019-01-10
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT01185964 2017-04-14
A Study of Olaratumab in Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1/2 Completed
NCT01316263 2017-03-09
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
Eli Lilly and Company
Phase 2 Terminated
NCT00768391 2011-06-28
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Eli Lilly and Company
Phase 1 Completed